Australian Stroke and Heart Research Accelerator (ASHRA) seminar series 2024
Chair: Professor Rebecca Ritchie – Monash Institute of Pharmaceutical Sciences (MIPS); ASHRA Education and Training Leadership.
Presenter: Associate Professor Tracey Gaspari – Founder, Inosi Therapeutics; Head, IRAP Pharmacology Lab, Monash University.
Developing novel IRAP inhibitors to target fibrotic CVD: navigating the path from basic research to commercialisation.
Tracey leads the IRAP Pharmacology Group in the Department of Pharmacology, Monash University, where she pioneered the novel concept of targeting the enzyme, Insulin Regulated Aminopeptidase (IRAP) in cardiovascular disease, with a particular focus on reversal of fibrosis. Through this work she co-founded the spinout company, Inosi Therapeutics, backed by investment from IP Group and Monash Investment Holdings. Inosi Therapeutics is focused on the development of first-in-class, orally active IRAP inhibitors to treat difficult-to-reverse fibrosis. In collaboration with Inosi and the other co-founders, Tracey led the team that was successful in receiving an MRFF Targeted Translation Research Accelerator (TTRA) grant to develop IRAP inhibitors to treat diabetes-induced renal and cardiovascular disease. Her research continues to explore ways in which targeting IRAP can be beneficial in multiple inflammatory and fibrotic diseases.
Discussion; Q and A
Copy and paste this link into your browser to attend: https://georgehub.zoom.us/j/81834921189